← Back to headlines
Eli Lilly Acquires Merida Biosciences in Nearly $3 Billion Cash Deal
Pharmaceutical giant Eli Lilly has agreed to acquire autoimmune-focused biotech firm Merida Biosciences in an all-cash transaction valued at up to $2.9 billion. The acquisition expands Lilly’s pipeline in inflammatory and immune-mediated diseases.
31 Aug, 10:48 — 31 Aug, 11:23
The Story
Analyzing sources…
Source Diversity
Source Diversity
High (51/100)4 sources30/33
Spectrum spread— 3/5 buckets covered17/33
Far L
Left1
Left (1)
cnbc
Center1
Center (1)
investing-com
Right2
Right (2)
Barron'sseeking-alpha
Far R
Geographic diversity— 1 region4/34
US4
ℹAll sources from US region
Sources
Showing 4 of 4 sources
cnbcMostly Factual1h ago
Eli Lilly to buy Merida Biosciences in deal worth up to $2.88 billion
Eli Lilly plans to buy privately held Merida Biosciences for up to $2.88 billion in cash.
Read full article →Barron'sHigh1h ago
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. - Barron's
Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What It Means for the Stock. Barron's
Read full article →seeking-alphaMixed1h ago
Lilly to buy Merida Biosciences for up to $2.875B in cash
Read full article →investing-com1h ago
Lilly to acquire Merida Biosciences for up to $2.875 billion
By Investing.com
Read full article →Coverage Timeline
First report: investing-com · 31 Aug, 10:48|Full coverage: 4 · 34m|Window: 34m
Left-leaningCenterRight-leaning
Related Stories
German Inflation Climbs to 2.9 Percent in August Amid Energy Price Hikes
17m ago
Greece Launches Nationwide Price Cut Initiative Covering Over 1,700 Products
24m ago
Aon Nears $17 Billion Acquisition of KKR-Backed USI Insurance
28m ago
Honda and Nissan Partner to Develop Next-Generation Vehicle Software
30m ago